METASTATIC PANCREATIC CANCER

This study is testing a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. A small device that gives off a special type of radiation is placed directly into the tumor, and patients also receive standard chemotherapy. The main goal is to see…

This early-phase trial is testing whether adding Tumor Treatment Fields (TTF) – a device that sends low-intensity electric fields to the tumor – to a specific chemotherapy combination (protein-bound paclitaxel, cisplatin, and gemcitabine) can help control metastatic pancreatic ca…

This study tests a mix of four drugs (iparomlimab, tuvonralimab, chidamide, and chemotherapy) as a first treatment for people with metastatic pancreatic cancer that has spread. The goal is to see if the combination shrinks tumors and helps people live longer. About 33 adults will…

This study tests if adding a low-dose targeted drug (erlotinib) to standard chemotherapy works better for people with a specific, aggressive type of advanced pancreatic cancer called basal-like. About 104 participants will first have their tumor type identified, then receive eith…

This study is for people with metastatic pancreatic cancer that has spread and hasn't been treated yet. It tests a two-step approach: first, a low-dose mix of five chemotherapy drugs, then long-term maintenance with two targeted drugs (olaparib and pembrolizumab). The goal is to …

This study tests a drug called Kinisoquin™ to see if it can prevent dangerous blood clots in people with advanced pancreatic cancer. About 480 adults with metastatic or locally advanced pancreatic cancer who are starting chemotherapy will receive either Kinisoquin™ or a placebo. …

This early-phase study tests a two-part system: one radioactive substance helps doctors see pancreatic cancer tumors on scans, and another delivers targeted radiation therapy. The goal is to check safety and find the right dose in 30 adults with advanced pancreatic cancer that ha…

This study tests whether adding the experimental drug setidegrasib to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 614 adults whose cancer has spread and cannot be removed by surgery will receive eit…

This study tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults aged 18-75 who have not had prior treatment for their advanced cancer will take part. The goal is to see …

This study tests an experimental treatment for people with metastatic cancers (colorectal, pancreatic, ovarian, breast, and neuroendocrine tumors) that have not responded to standard therapy. Doctors take white blood cells from a patient's tumor, grow the most cancer-fighting one…

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug aims to block a protein (CD73) that helps tumors hide from the immune system. The trial first finds the safest dose alone, then tests it with chemotherapy and an…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with pancreatic, breast, or other solid t…

This study tests a new approach for advanced pancreatic cancer that cannot be removed by surgery. Doctors place tiny devices called Alpha DaRT seeds directly into the tumor to deliver a special type of radiation from the inside. The main goals are to see if the procedure is safe …

This early-stage study tests a new drug called ERX-315 in people with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that no longer respond to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. About 15 …

This study tests whether giving two different chemotherapy regimens one after the other (first Gembrax, then Folfirinox) helps people with metastatic pancreatic cancer live longer without their disease getting worse, compared to using Folfirinox alone. About 162 adults aged 18 to…

This study aims to find genetic changes in the tumors of 750 people with advanced or metastatic pancreatic cancer. By identifying these changes, doctors hope to match patients with targeted treatments that may work better for them. The study does not test a new drug but collects …